Scholar RockSRRK
SRRK
About: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Employees: 150
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
544% more capital invested
Capital invested by funds: $698M [Q3] → $4.49B (+$3.8B) [Q4]
350% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 9 (+7) [Q4]
310% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 20
44% more call options, than puts
Call options by funds: $75.1M | Put options by funds: $52.2M
38% more funds holding
Funds holding: 160 [Q3] → 220 (+60) [Q4]
2.28% more ownership
Funds ownership: 108.77% [Q3] → 111.05% (+2.28%) [Q4]
10% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 61
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
19%
upside
Avg. target
$47
26%
upside
High target
$50
33%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andres Maldonado 27% 1-year accuracy 12 / 45 met price target | 33%upside $50 | Buy Maintained | 26 Nov 2024 |
Wedbush David Nierengarten 35% 1-year accuracy 45 / 127 met price target | 25%upside $47 | Outperform Maintained | 25 Nov 2024 |
Truist Securities Srikripa Devarakonda 34% 1-year accuracy 12 / 35 met price target | 19%upside $45 | Buy Maintained | 25 Nov 2024 |
Financial journalist opinion
Based on 6 articles about SRRK published over the past 30 days
Neutral
Business Wire
23 hours ago
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March.
Neutral
Business Wire
1 week ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 371,500 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to.
Neutral
Business Wire
1 week ago
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its fourth quarter and full year 2024 financial results and provide a business update on Thursday, February 27, 2025, at 8:15am ET. To acce.
Positive
Seeking Alpha
3 weeks ago
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders.
Neutral
Business Wire
3 weeks ago
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for apitegromab, a muscle-targeted therapy designed and developed to provide clinically meaningfu.
Neutral
Business Wire
3 weeks ago
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that Lisa Wyman has been appointed to the new role of Chief Technical and Quality Officer (CTQO) to support the Company's ongoing growth and evolution to becoming a fully integrated biopharma co.
Neutral
Business Wire
1 month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 48,000 shares of its common stock to three newly hired employees, consisting of inducement stock options to pu.
Positive
Benzinga
1 month ago
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.
Neutral
Business Wire
1 month ago
Scholar Rock Highlights 2025 Strategic Priorities
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2025. “We are excited about the potential for apitegromab to help those living with SMA as the first and only muscle-targeted ther.
Neutral
Business Wire
1 month ago
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:45 a.m. PT (12:45 p.m. ET). A live webcast of the presentation may be accesse.
Charts implemented using Lightweight Charts™